Make an Appointment

Ask a Question
Refer a Patient

1.877.CALL NJH
(877.225.5654)

National Jewish Statement Regarding Serevent

Serevent is an effective drug for the treatment of both asthma and chronic obstructive pulmonary disease (COPD) when used appropriately.

Previous research has indicated that a very small number of asthma patients may be at increased risk for adverse effects from the medication. A warning to that effect has been on medications containing Serevent for more than a year.

We are aware of no new data indicating a greater risk than has already been identified and highlighted. We are aware of no data indicating an increased risk for COPD patients taking Serevent.

All asthma patients taking Serevent should also be taking an inhaled steroid.

Patients who are doing well on Serevent, should continue using it. Patients who feel that their asthma symptoms are worsening should contact their physician.

Patients should never stop using Serevent or any other asthma medication without consulting their physician. Untreated asthma poses a greater risk than the potential risk posed by Serevent.

Serevent is a long-acting beta agonist controller therapy and should not be used as a rescue medication. Patients taking Serevent should continue to have available short-acting beta agonists, such as albuterol, as their rescue medication.

Patients who are just beginning to take Serevent should experience a benefit within a short time. If not, they should talk to their physician.

Bookmark and Share

News Archive
Browse by Year

Search All

2014
|
2013
|
2012
|
2011

2010
|
2009
|
2008
|
2007
2006
2005
2004
2003
2002
Media Contacts

Newsroom

In the Newsroom, you can find National Jewish Health press releases, newsletters, annual reports and media contacts. Learn more.

 

Sign Up for e-Newsletters

Enter your email address to receive health tips, recent research findings and news about National Jewish Health.